Coronavirus

Pfizer Backs Out Of Emergency Use Request For Vaccine In India; Know Why

By
OB Bureau

New Delhi: Pfizer has decided to withdraw the application for emergency use authorisation of its COVID-19 vaccine in India, the pharmaceutical major said on Friday.

Incidentally, the US company was the first firm to seek the emergency use authorisation from the Drugs Controller General of India (DCGI) for its vaccine, after it had secured similar approvals in the UK and Bahrain.

According to sources, Pfizer’s decision to withdraw its application followed a meeting with DCGI’s Subject Expert Committee earlier on Wednesday.

Confirming this, a Pfizer statement said, “Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time.”

The company, however, added that it will resubmit the approval request with additional information in the near future, NDTV reported.

“Pfizer remains committed to making its vaccine available for use by the Government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment,” the statement said.

Behind The Scenes

Pfizer had sought authorisation for its vaccine in India late last year, but the government in January approved two much cheaper shots — one from Oxford University/AstraZeneca and another developed at home by Bharat Biotech with the Indian Council of Medical Research. Both companies had applied for approval of their vaccines after Pfizer.

Pfizer’s Take

The US company had claimed that its application was supported by data from a global study that showed an overall efficacy rate of 95 per cent with no vaccine-related, serious safety concerns, Reuters reported.

Drugs Controller Stand

However, the Central Drugs Standard Control Organisation had declined to accept Pfizer’s request for approval without a small local trial on the vaccine’s safety and immunogenicity for Indians, according to an India Today report.

Health officials said they generally ask for so-called bridging trials to determine if a vaccine is safe and generates an immune response in Indian citizens whose genetic makeup can be different from people in Western nations.

OB Bureau

Recent Posts

Thalassemia & Sickle Cell Patients Stage Dharna For Blood Transfusion Centre At MKCG Hospital In Odisha’s Berhampur

Berhampur: Hundreds of thalassemia and sickle cell patients on Tuesday staged a demonstration demanding a…

November 26, 2024

Samantha Ruth Prabhu Was Labelled ‘Second Hand’, ‘Used’ After Divorce With Naga Chaitanya

Mumbai: Actress Samantha Ruth Prabhu and her ex-husband actor Naga Chaitanya have moved on after…

November 26, 2024

Amid Divorce Rumours, Aishwarya Asks Women To Never Compromise On Their Worth [Watch]

Mumbai: Amidst rumours of their divorce, Bollywood queen Aishwarya Rai asked women to stand up…

November 26, 2024

Prime Minister Modi To Participate In Roadshow On Arrival In Bhubaneswar

Bhubaneswar: Prime Minister Narendra Modi will participate in a roadshow on his arrival at Bhubaneswar…

November 26, 2024

How Custody Battle With Elon Musk Left His Ex-Girlfriend Grimes ‘Bankrupt’

New York: Elon Musk, father of 12 children with different partners, has led an eventful…

November 26, 2024

Vigilance Apprehends College Principal While Taking Rs 1 Lakh Bribe In Odisha’s Nayagarh

Bhubaneswar: Vigilance has apprehended a college principal while taking a bribe of Rs 1 lakh…

November 26, 2024

FIR Against ‘Pushpa 2’ Actor Shri Tej For Cheating & Exploiting Woman

Mumbai: Ahead of the release of Allu Arjun's highly-anticipated ‘Pushpa: The Rule’, one of the…

November 26, 2024

Odisha Govt Rejects IAS Officer Sujata Karthikeyan’s Leave Extension Application

Bhubaneswar: The Odisha government has rejected the application of IAS officer Sujata R Karthikeyan for…

November 26, 2024